Abstract 39P
Background
Prostate cancer (PCa) is one of the leading malignant diseases in men worldwide. The presence of myeloid-derived suppressor cells (PMN-MDSCs) is a critical contributor to a pro-tumorigenic microenvironment in advanced disease, where the neutrophil-lymphocyte ratio (NLR) is prognostic. However, their involvement in the early stages of PCa is still unclear.
Methods
Patients affected by localized prostate cancer and undergoing radical prostatectomy at the Urology Department of the University Hospital of Padua were enrolled in the study after signing informed consent. Blood and tumor samples from 79 patients were collected and immunostained for flow cytometry analysis. Disease risk groups were assigned according to EAU guidelines. Correlation between experimental data and clinical and anatomopathological features was done by logistic regression and Sperman’s correlation.
Results
No association between neutrophil counts and NLR with oncological outcome was found in a population of 79 patients with localized prostate cancer. However, a subset of circulating immature myeloid cells was found to be associated with higher disease risk groups (OR = 1.19 CI.95 (1.02, 1.38), p-value = 0.027). Of note, primary tumor lesions did not reveal a significant enrichment of the immune infiltrate and any association with clinical scores. Further analyses on defining a new potential circulating biomarker showed encouraging results. Gene expression analyses are ongoing.
Conclusions
Localized PCa is not associated with a higher circulating number of neutrophils and higher NLR compared with healthy subjects. However, further analyses of specific myeloid cell subsets are needed.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract